Sandy Griffith

2.5k citations

17 papers · 507 indexed · h-index 10

Impact in

Virology top 2%
- HIV Research and Treatment
Infectious Diseases top 5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Infectious Diseases 15
- HIV/AIDS drug development and treatment 14
- HIV/AIDS Research and Interventions 11
Virology 12
- HIV Research and Treatment 12

Co-authors: William Spreen (9 shared papers)Krischan J Hudson (7 shared papers)Susan L. Ford (3 shared papers)Kimberly Y. Smith (2 shared papers)David M. Margolis (9 shared papers)Jerome De Vente (1 shared paper)Graham Smith (1 shared paper)Britt Stancil (1 shared paper)
Journals: Open Forum Infectious Diseases (6 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (2 papers)AIDS and Behavior (2 papers)Journal of the International AIDS Society (1 paper)BMC Infectious Diseases (1 paper)
Partner nations: United States Belgium Canada

In The Last Decade

Sandy Griffith

17 papers receiving 494 citations

Peers

Countries citing papers authored by Sandy Griffith

Since Specialization

Citations

This map shows the geographic impact of Sandy Griffith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandy Griffith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandy Griffith more than expected).

Fields of papers citing papers by Sandy Griffith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandy Griffith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandy Griffith. The network helps show where Sandy Griffith may publish in the future.

Co-authors

The 25 scholars most cited alongside Sandy Griffith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandy Griffith Line = papers co-authored together Sandy Griffith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial The Lancet Infectious Diseases ·David A. Margolis, Cynthia Brinson, Graham Smith, Jerome De Vente, Debbie Hagins, Joseph J. Eron, Sandy Griffith, M H St Clair, Marita Stevens, Peter Williams, Susan L. Ford, Britt Stancil, M Bomar, Krischan J Hudson, Kimberly Y. Smith, William Spreen	2015	157
2	Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study The Lancet HIV ·Chloe Orkin, Enrique Bernal, Darrell H. S. Tan, Harold Katner, Hans‐Jürgen Stellbrink, Elena Belonosova, Rebecca DeMoor, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen‐Ristea, Susan L. Ford, Herta Crauwels, Parul Patel, Amy Cutrell, Kimberly Y. Smith, Kati Vandermeulen, Eileen Birmingham, Marty St. Clair, William Spreen, Ronald D’Amico	2021	88
3	Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine JAIDS Journal of Acquired Immune Deficiency Syndromes ·John Bartlett, Judy Johnson, Gisela Herrera, Néstor Sosa, Alan Rodriguez, Qiming Liao, Sandy Griffith, David M. Irlbeck, Mark S. Shaefer	2006	56
4	Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks AIDS and Behavior ·Miranda Murray, Antonio Antela, Anthony Mills, Jenny Huang, H. de Jager, Enrique Bernal, Johan Lombaard, Harold Katner, Sharon Walmsley, Marie-Aude Khuong-Josses, Krischan J Hudson, David Dorey, Sandy Griffith, William Spreen, Simon Vanveggel, Mark S. Shaefer, David M. Margolis, Vasiliki Chounta	2020	53
5	Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects British Journal of Clinical Pharmacology ·Ann K. Miller, Emma Harrell, Ye Li, Sharon Baptiste‐Brown, Jőrg‐Peter Kleim, Colin Ohrt, Stephan Duparc, Jörg J. Möhrle, Alison Webster, Sandra S. Stinnett, Arlene R. Hughes, Sandy Griffith, Andrew P. Beelen	2013	36
6	Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials AIDS and Behavior ·Andrea Mantsios, Miranda Murray, Tahilin Sanchez Karver, Wendy Davis, David M. Margolis, Princy Kumar, Susan Swindells, U. Fritz Bredeek, Miguel García Deltoro, Mercedes García‐Gasalla, Rafael Rubio, Antonio Antela, Krischan J Hudson, Sandy Griffith, Deanna Kerrigan	2020	35
7	Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study SHILAP Revista de lepidopterología ·Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Hans Jaeger, (unknown), David Dorey, Sandy Griffith, Joseph Mrus, William Spreen, David M. Margolis	2019	26
8	2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies Open Forum Infectious Diseases ·Parul Patel, Susan L. Ford, Herta Crauwels, Kelong Han, Stefaan Rossenu, Martine Neyens, Sandy Griffith, Krischan J Hudson, David M. Margolis, Mark Baker, Peter Williams, William Spreen	2019	17
9	Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients BMC Infectious Diseases ·Jeffrey P. Nadler, Joseph Gathe, Richard B. Pollard, Gary Richmond, Qiming Liao, Sandy Griffith, C. Tracey Lancaster, Jaime E. Hernández, Keith A. Pappa, (unknown)	2003	11
10	P032: Dolutegravir versus raltegravir in ARV-experienced INI-naïve HIV+ adults: 48-week subgroup analysis of Latin American subjects in the SAILING study Journal of the International AIDS Society ·Pedro Cahn, Jaime Andrade‐Villanueva, Carlos Beltrán, Tâmara Newman, David Dorey, Dannae Brown, Isidoro Prudente, Sandy Griffith, Michael Aboud, Carlos Fernando de Oliveira	2015	9
11	884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies Open Forum Infectious Diseases ·Paula Teichner, Amy Cutrell, Ronald D’Amico, David Dorey, Sandy Griffith, Conn Harrington, Jenny Huang, Krischan J Hudson, David M. Margolis, Joseph Mrus, Joseph W. Polli, William Spreen, Peter Williams, Rodica Van Solingen‐Ristea, Mark S. Shaefer	2019	4
12	1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome Open Forum Infectious Diseases ·Christine L. Talarico, Sterling Wu, Ojesh R Upadhyay, Marty St. Clair, Veerle Van Eygen, Krischan J Hudson, Sandy Griffith, Conn Harrington, Jan van Lunzen, David M. Margolis, William Spreen	2020	4
13	1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results Open Forum Infectious Diseases ·Vasiliki Chounta, Enrique Bernal, Johan Lombaard, Harold Katner, Sharon Walmsley, David Dorey, William Spreen, Sandy Griffith, David M. Margolis	2020	4
14	1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies Open Forum Infectious Diseases ·Paula Teichner, Sterling Wu, Feifan Zhang, David Dorey, Ronald D’Amico, Sandy Griffith, Kenneth Sutton, Cynthia McCoig, Ojesh R Upadhyay, Joseph W. Polli, David M. Margolis, Rodica Van Solingen‐Ristea, Kati Vandermeulen, William Spreen, Parul Patel	2020	2
15	LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials Open Forum Infectious Diseases ·Ronald D’Amico, Paul Benn, Cynthia McCoig, Sandy Griffith, Krischan J Hudson, Kenneth Sutton, Conn Harrington, Sterling Wu, Will Williams, Kai Hove, Carlos Martín Español, E Jane Fricker, Parul Patel, David M. Margolis	2020	2
16	Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials JAIDS Journal of Acquired Immune Deficiency Syndromes ·Maggie Czarnogorski, Paul Benn, Cindy McCoig, Toyin Nwafor, Sandy Griffith, Ken Sutton, Conn Harrington, Parminder Saggu, Itziar Yague, Will Williams, Carlos Martín Español, Jessica Goodchild, Jane Fricker, Parul Patel, Ronald D’Amico	2022	2
17	A prospective, multicenter, open-label, clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for treatment of unresectable hepatocellular carcinoma (HCC): DOORwaY90 HPB ·Armeen Mahvash, Suzanne Chartier, Marco Rosselli Del Turco, P. Habib, Sandy Griffith, Sheldon T. Brown, S. Cheenu Kappadath	2021	1

About Sandy Griffith

Sandy Griffith is a scholar working on Infectious Diseases, Virology, Epidemiology, Hepatology and Pharmacology, having authored 17 papers that have together received 507 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (12 papers), HIV/AIDS Research and Interventions (11 papers), Hepatitis C virus research (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (1 paper), Cancer Genomics and Diagnostics (1 paper) and HIV, Drug Use, Sexual Risk (1 paper). The work is most often cited by research in Virology (322 citations), Infectious Diseases (442 citations), Emergency Medicine (78 citations), Epidemiology (115 citations) and Hepatology (23 citations). Sandy Griffith has collaborated with scholars based in United States, Belgium and Canada. Frequent co-authors include William Spreen, Krischan J Hudson, Susan L. Ford, Kimberly Y. Smith, David M. Margolis, Jerome De Vente, Graham Smith, Britt Stancil, M H St Clair and Debbie Hagins. Their work appears in journals such as Open Forum Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes, AIDS and Behavior, Journal of the International AIDS Society and BMC Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact